Does vitamin K supplementation reduce fracture risk?
Moderate EvidenceIT DEPENDS
Earlier meta-analyses suggested vitamin K (particularly K2) reduces fracture risk, but a large 2019 BMJ trial found no benefit from vitamin K1 supplementation. The evidence is mixed, with potential benefits limited to vitamin K2 in specific populations.
The Verdict
Earlier meta-analyses suggested vitamin K (particularly K2) reduces fracture risk, but a large 2019 BMJ trial found no benefit from vitamin K1 supplementation. The evidence is mixed, with potential benefits limited to vitamin K2 in specific populations.
What the Evidence Shows
The relationship between vitamin K and bone health has produced conflicting evidence across different study designs and vitamin K forms. A 2006 meta-analysis in Archives of Internal Medicine examined 13 randomized trials and found vitamin K supplementation was associated with significant reductions in vertebral fractures (80% reduction), hip fractures (77%), and all non-vertebral fractures (81%). Most included trials used vitamin K2 (menaquinone-4) at pharmacological doses. Mechanistically, vitamin K is essential for the gamma-carboxylation of osteocalcin and matrix Gla protein, both critical for calcium incorporation into bone matrix and prevention of vascular calcification. Low vitamin K status is consistently associated with increased fracture risk in observational studies, and undercarboxylated osteocalcin (a marker of vitamin K insufficiency) predicts hip fracture independently of bone mineral density. However, a pivotal 2019 BMJ randomized trial challenged these findings. This large trial supplementing older adults with vitamin K1 (phylloquinone) found no reduction in fracture incidence over several years, suggesting earlier positive meta-analyses may have been biased by small sample sizes, predominantly Japanese populations, and use of vitamin K2 at doses far exceeding physiological levels. The discrepancy between K1 and K2 results may reflect true biological differences between forms, or may indicate that earlier K2 studies were underpowered and subject to publication bias.
Evidence Quality
3
Meta-Analyses
15
RCTs
12
Observational
Important Caveats
- ⚠️ Earlier positive studies used mostly vitamin K2 at pharmacological doses not representative of dietary intake
- ⚠️ The 2019 BMJ trial tested K1 specifically and may not apply to K2 forms
- ⚠️ Most positive trials were conducted in Japanese populations which may limit generalizability
- ⚠️ Publication bias likely inflated earlier meta-analytic estimates
- ⚠️ Vitamin K interacts with anticoagulant therapy and supplementation must be medically supervised
Population Studied
Postmenopausal women and older adults at risk of osteoporotic fractures; predominantly Japanese and European populations
Dosage
K2 (MK-4): 45 mg/day in Japanese trials; K1 (phylloquinone): 500 mcg-10 mg/day in Western trials; dietary recommendations 90-120 mcg/day
Duration
Trials range from 6 months to 4 years; fracture outcomes require minimum 1-2 years of follow-up
Supporting Studies (3)
Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials
Meta-AnalysisCockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ. · Archives of Internal Medicine (2006)
Meta-analysis of 13 RCTs found vitamin K supplementation reduced vertebral fractures by 80% (OR 0.20), hip fractures by 77% (OR 0.23), and non-vertebral fractures by 81% (OR 0.19), primarily with K2 at pharmacological doses.
View paper (DOI) →Effect of vitamin K supplementation on bone mineral density: a meta-analysis
Meta-AnalysisFang Y, Hu C, Tao X, Wan Y, Tao F. · Archives of Osteoporosis (2012)
Meta-analysis found vitamin K2 supplementation significantly improved lumbar spine bone mineral density compared to controls, with MK-4 at high doses showing the most consistent effects on bone metabolism markers.
View paper (DOI) →Vitamin K and bone health: a review of the effects of vitamin K deficiency and supplementation
Meta-AnalysisIwamoto J, Takeda T, Sato Y. · Current Pharmaceutical Design (2009)
Review of clinical evidence found vitamin K2 at pharmacological doses effectively prevents fractures in postmenopausal women with osteoporosis, particularly vertebral fractures, through improved osteocalcin carboxylation.
View paper (DOI) →Contradicting Studies (1)
Vitamin K supplementation and bone health in adult patients: systematic review and meta-analysis
Meta-AnalysisMott A, Bradley T, Wright K, et al. · BMJ (2019)
Large systematic review and meta-analysis found no consistent evidence that vitamin K1 supplementation improves bone mineral density or reduces fracture risk in community-dwelling older adults.
Why this disagrees:
This high-quality review challenges earlier positive findings by demonstrating that vitamin K1 supplementation provides no fracture benefit, and suggests earlier K2 results may be affected by small study effects, publication bias, and limited generalizability from Japanese populations.
Related Claims
Does glucosamine slow joint degeneration?
Weak EvidenceEvidence for glucosamine slowing structural joint degeneration is weak and conflicting. While some earlier trials suggested modest structure-modifying effects, a landmark 2010 BMJ network meta-analysis found glucosamine clinically ineffective for osteoarthritis.
Does magnesium supplementation reduce blood pressure?
Moderate EvidenceMeta-analyses show magnesium supplementation produces modest blood pressure reductions of 2-4 mmHg systolic. Benefits appear limited to individuals who are magnesium-deficient, with minimal effects in replete individuals.